Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17483064rdf:typepubmed:Citationlld:pubmed
pubmed-article:17483064lifeskim:mentionsumls-concept:C0005961lld:lifeskim
pubmed-article:17483064lifeskim:mentionsumls-concept:C0043162lld:lifeskim
pubmed-article:17483064lifeskim:mentionsumls-concept:C0006463lld:lifeskim
pubmed-article:17483064lifeskim:mentionsumls-concept:C0009647lld:lifeskim
pubmed-article:17483064lifeskim:mentionsumls-concept:C0059985lld:lifeskim
pubmed-article:17483064lifeskim:mentionsumls-concept:C0332257lld:lifeskim
pubmed-article:17483064lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:17483064pubmed:issue3lld:pubmed
pubmed-article:17483064pubmed:dateCreated2007-5-7lld:pubmed
pubmed-article:17483064pubmed:abstractTextWe investigated the feasibility of reduced-intensity conditioning with 4 Gy total body irradiation, fludarabine (30 mg/m2 for 6 days), and busulfan (4 mg/kg for 2 days) for bone marrow transplantation from a serologically HLA-matched unrelated donor. Seventeen adult patients (median age, 55 years; range, 27-67 years) with various hematologic malignancies (6 in remission, 11 not in remission) were treated. Successful engraftment was achieved in all patients at a median of day 18 (range, day 14-35) after transplantation, although subsequent secondary graft failure was observed in 2 patients. The cumulative incidence of acute graft-versus-host disease (GVHD) of grades II to IV at day 100 was 48%. With a median follow-up of 286 days (range, 56-687 days), the rates of 1-year overall survival, 100-day nonrelapse mortality, and 1-year nonrelapse mortality were 41%, 14%, and 46%, respectively. Eleven patients died, and the causes of death were relapse (n = 4), pulmonary complications (n = 4), acute GVHD (n = 2), and sepsis (n = 1). The remaining 6 patients (at transplantation, 2 were in remission, and 4 were not in remission) are currently still in remission. These results suggest that this regimen reduces the risk of graft failure, but further studies are needed to ameliorate transplantation-related toxicities, primarily GVHD and/or pulmonary complications.lld:pubmed
pubmed-article:17483064pubmed:languageenglld:pubmed
pubmed-article:17483064pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17483064pubmed:citationSubsetIMlld:pubmed
pubmed-article:17483064pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17483064pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17483064pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17483064pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17483064pubmed:statusMEDLINElld:pubmed
pubmed-article:17483064pubmed:monthAprlld:pubmed
pubmed-article:17483064pubmed:issn0925-5710lld:pubmed
pubmed-article:17483064pubmed:authorpubmed-author:TobinaiKensei...lld:pubmed
pubmed-article:17483064pubmed:authorpubmed-author:HeikeYujiYlld:pubmed
pubmed-article:17483064pubmed:authorpubmed-author:TakaueYoichiYlld:pubmed
pubmed-article:17483064pubmed:authorpubmed-author:TanosakiRyuji...lld:pubmed
pubmed-article:17483064pubmed:authorpubmed-author:MoriShin-ichi...lld:pubmed
pubmed-article:17483064pubmed:authorpubmed-author:KimSung-WonSWlld:pubmed
pubmed-article:17483064pubmed:authorpubmed-author:OnishiYasushi...lld:pubmed
pubmed-article:17483064pubmed:authorpubmed-author:FukudaTakahir...lld:pubmed
pubmed-article:17483064pubmed:authorpubmed-author:KusumotoShige...lld:pubmed
pubmed-article:17483064pubmed:authorpubmed-author:AkahaneDaigoDlld:pubmed
pubmed-article:17483064pubmed:authorpubmed-author:SugimotoKyoko...lld:pubmed
pubmed-article:17483064pubmed:authorpubmed-author:Morita-HoshiY...lld:pubmed
pubmed-article:17483064pubmed:issnTypePrintlld:pubmed
pubmed-article:17483064pubmed:volume85lld:pubmed
pubmed-article:17483064pubmed:ownerNLMlld:pubmed
pubmed-article:17483064pubmed:authorsCompleteYlld:pubmed
pubmed-article:17483064pubmed:pagination256-63lld:pubmed
pubmed-article:17483064pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:meshHeadingpubmed-meshheading:17483064...lld:pubmed
pubmed-article:17483064pubmed:year2007lld:pubmed
pubmed-article:17483064pubmed:articleTitleUnrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation.lld:pubmed
pubmed-article:17483064pubmed:affiliationDivision of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.lld:pubmed
pubmed-article:17483064pubmed:publicationTypeJournal Articlelld:pubmed